ESPR Q4 2023 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$32M+71.4% YoY

Gross Profit

$21M64.5% margin

Operating Income

-$42M-131.4% margin

Net Income

-$56M-174.7% margin

EPS (Diluted)

$-0.50

QoQ Revenue Growth

-5.1%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$206M

Total Liabilities

$661M

Stockholders' Equity

-$455M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$19M	+71.4%
Gross Profit	$21M	$15M	+41.9%
Operating Income	-$42M	-$43M	+0.3%
Net Income	-$56M	-$55M	-1.5%

Revenue Segments

Product

$21M64%

Collaboration Revenue

$11M36%